PLEASANTON, Calif.,
Nov. 27, 2012 /PRNewswire/ -- TriReme
Medical, Inc. and its affiliates (TriReme) announced today a new
round of financing that brings a total of US$18 million into the group. The round is led by
Luminor Capital of Singapore and
includes major existing investors and new Asian investors. TriReme
provides a range of innovative solutions for complex lesions and
proceeds of the new round will go toward developing TriReme's
pipeline of unique dilatation catheters and expanding its
commercial infrastructure worldwide.
"We are thrilled to have this major support from Asia in our efforts to create a next
generation of interventional devices, " stated Eitan Konstantino, Ph.D., President and CEO of
TriReme Medical. "We share a vision of leaving no implant behind
and will continue to focus on the large Asian markets in addition
to the US."
"TriReme has demonstrated significant commercial and technical
progress despite many challenges that the medical device community
is facing," said Mr. Michael Kleine
representing TriReme's board of directors. "Together with our new
partners, we are looking forward to supporting the company in the
commercialization of its breakthrough technologies."
In a related announcement, TriReme welcomes Mr. John Borrell as Vice President of Sales. Mr.
Borrell is a seasoned sales executive with vast experience
including senior management positions held at Covidien, CSI, and
FoxHollow.
About TriReme Medical, Inc.
Based in Pleasanton, California and Singapore, TriReme Medical, Inc. is a
privately held medical device company dedicated to the development,
manufacturing, and commercialization of next generation
percutaneous devices for the treatment of complex coronary and
peripheral arterial disease. The company is focused on the US and
the emerging Asian markets.
SOURCE TriReme Medical, Inc.